In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Nurix Therapeutics Inc (NASDAQ: NRIX) closed the day trading at $18.59 down -1.90% from the previous closing price of $18.95. In other words, the price has decreased by -$1.90 from its previous closing price. On the day, 0.81 million shares were traded. NRIX stock price reached its highest trading level at $19.355 during the session, while it also had its lowest trading level at $18.29.
Ratios:
For a better understanding of NRIX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.46 and its Current Ratio is at 6.46. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $35.UBS initiated its Buy rating on October 24, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’25 when Ring Christine sold 5,760 shares for $19.95 per share. The transaction valued at 114,934 led to the insider holds 32,538 shares of the business.
CHRISTINE RING bought 5,760 shares of NRIX for $115,286 on Jan 31 ’25. On Jan 30 ’25, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 3,220 shares for $19.85 each. As a result, the insider received 63,929 and left with 32,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1410735616 and an Enterprise Value of 964648704. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.86 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 17.096 whereas that against EBITDA is -5.175.
Stock Price History:
The Beta on a monthly basis for NRIX is 2.15, which has changed by 1.2858865 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $7.92. The 50-Day Moving Average of the stock is -7.84%, while the 200-Day Moving Average is calculated to be -9.93%.
Shares Statistics:
Over the past 3-months, NRIX traded about 892.84K shares per day on average, while over the past 10 days, NRIX traded about 595140 shares per day. A total of 75.87M shares are outstanding, with a floating share count of 73.79M. Insiders hold about 2.76% of the company’s shares, while institutions hold 89.05% stake in the company. Shares short for NRIX as of 1736899200 were 10865940 with a Short Ratio of 12.17, compared to 1734048000 on 9830540. Therefore, it implies a Short% of Shares Outstanding of 10865940 and a Short% of Float of 16.459998000000002.
Earnings Estimates
The performance of Nurix Therapeutics Inc (NRIX) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.55 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.42 and -$3.82 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$3.18, with 11.0 analysts recommending between -$1.62 and -$4.78.
